Harpoon Therapeutics’ (NASDAQ:HARP) quiet period is set to end on Wednesday, March 20th. Harpoon Therapeutics had issued 5,400,000 shares in its initial public offering on February 8th. The total size of the offering was $75,600,000 based on an initial share price of $14.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Several equities analysts recently issued reports on the stock. Wedbush assumed coverage on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. They issued an “outperform” rating and a $23.00 target price on the stock. Svb Leerink restated an “outperform” rating on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. Finally, Canaccord Genuity assumed coverage on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. They issued a “buy” rating and a $24.00 target price on the stock.
Harpoon Therapeutics stock opened at $11.76 on Wednesday. Harpoon Therapeutics has a twelve month low of $11.23 and a twelve month high of $17.85.
In related news, Director Luke Evnin acquired 250,000 shares of the stock in a transaction dated Tuesday, February 12th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $3,500,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bioscience Plc Arix acquired 428,571 shares of the stock in a transaction dated Tuesday, February 12th. The shares were bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here.
COPYRIGHT VIOLATION WARNING: “Harpoon Therapeutics Inc’s Quiet Period To Expire on March 20th (NASDAQ:HARP)” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/13/harpoon-therapeutics-incs-quiet-period-to-expire-on-march-20th-nasdaqharp.html.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer.
Read More: Understanding Stock Ratings
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.